Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating children's hyperactivity

A technology for children with ADHD, composition, applied in the field of medicine

Active Publication Date: 2012-04-18
CHONGQING TECH & BUSINESS UNIV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In view of this, the purpose of the present invention is to provide a pharmaceutical composition that can solve the problem of ADHD caused by children's brain neurodevelopment, and can improve the symptoms of ADHD, and achieve the purpose of "treating both symptoms and root causes".

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating children's hyperactivity
  • Pharmaceutical composition for treating children's hyperactivity
  • Pharmaceutical composition for treating children's hyperactivity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] In order to further understand the present invention, the present invention will be described in detail below with reference to the embodiments. Example 1: Influence of the pharmaceutical composition of the present invention on the content of norepinephrine in rat brain tissue

[0018] Experimental animals: 36 healthy male SHR rats, aged 10 weeks, weighing 265-295 g, were purchased from the Institute of Laboratory Animals, Sichuan Academy of Medical Sciences.

[0019] Grouping and administration: The rats were randomly divided into blank control group, atomoxetine hydrochloride group, atomoxetine hydrochloride and vitamin B6 groups with different ratios, 6 rats in each group, and administered by gavage. The atomoxetine hydrochloride and vitamin B6 different ratio groups and atomoxetine hydrochloride group were all 10 mg / kg, and the blank control group was given the same dose of 0.9% NaCl, every morning, once a day, for 14 days. During the experiment, each rat was given...

Embodiment 2

[0024] Example 2: Influence of the pharmaceutical composition of the present invention on the repair of neuron damage in rat brain tissue

[0025]Experimental animals: Wistar rats, within 48 hours of birth, were purchased from the Institute of Laboratory Animals, Sichuan Academy of Medical Sciences.

[0026] Cell culture: Wistar rats within 48 hours of birth were taken out, sterilized, and the cerebral cortex was isolated under sterile conditions, washed twice with PBS solution, and digested in 0.25% trypsin for 30 min. Discard the surface trypsin with a pipette. DMEM high-glucose medium containing 10% fetal bovine serum was added, centrifuged at 1000 r / min for 3 min, and the supernatant was aspirated to prepare a single-cell suspension. After the natural sedimentation, the upper single cell suspension was transferred to another centrifuge tube, and the same method was repeated to finally obtain the cell suspension. Inoculated in a 6-well culture plate, placed at 37°C, 5% CO...

Embodiment 3

[0032] Example 3: Tablets for the treatment of ADHD in children

[0033] Recipe composition (calculated by 1000 tablets)

[0034]

[0035] Preparation method: Weigh atomoxetine hydrochloride, vitamin B6, mannitol, starch, magnesium stearate, micropowder silica gel, mix thoroughly, add an appropriate amount of distilled water, stir and granulate, pass through a 20-mesh sieve, dry, and press into tablets, each tablet is about 0.3 g .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines and specifically to a pharmaceutical composition for treating children's hyperactivity. The pharmaceutical composition for treating children's hyperactivity in the invention comprises tomoxetine hydrochloride and vitamin B6, and the mass ratio of tomoxetine hydrochloride to vitamin B6 is 1: 0.5 to 1:4; tomoxetine hydrochloride and vitamin B6 can be compounded with normal accessories to prepare a medicine for treating children's hyperactivity. According to the invention, composition of tomoxetine hydrochloride and vitamin B6 which weighs 0.5 to 4times of tomoxetine hydrochloride has a synergistic effect, can substantially enhance the upturning effect of NA, promote the development of brain nerves and stabilizing the functions of brain cells,and produces an effect of simultaneous treatment of principal and subordinate symptoms on children's hyperactivity.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a pharmaceutical composition for treating ADHD in children. Background technique [0002] ADHD, also known as Attention Deficit Hyperactivity Disorder (ADHD), or Mild Brain Dysfunction Syndrome, is a common behavioral disorder in children that causes abnormal behavior in children. According to foreign reports, the prevalence of ADHD in children is between 5% and 10%, and the domestic survey is more than 10%. The probability of premature infants suffering from ADHD is the highest, about 60%, and boys are much more than girls. Children with ADHD have normal or basically normal intelligence, but have deficits in learning, behavior, and emotions, mainly manifested as inattention, short attention span, hyperactivity, impulsivity, generally poor academic performance, and poor academic performance at home and school. It is difficult to get along with others, and parents and teachers often feel ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4415A61P25/00A61K31/138
Inventor 汪程远郑旭煦殷钟意陈刚
Owner CHONGQING TECH & BUSINESS UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com